Targeted Oncology21m
Fedratinib Shows Safety, Potential as Post-Transplant Therapy in MPNs
Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Targeted Oncology2h
Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
Targeted Oncology5h
FDA Grants Fast Track Designation to 67Cu-SAR-bisPSMA in mCRPC
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Targeted Oncology9h
CARTITUDE-4 Highlights: Cilta-Cel vs Standard of Care in R/R MM
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Targeted Oncology9h
Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...